利妥昔单抗时代滤泡性淋巴瘤移植治疗的现状及前景  

The present situation and future of transplantation therapy for follicular lymphoma in the time of rituximab

作　　者：陈晓晨[1] 吴德沛[1] 

机构地区：[1]苏州大学附属第一医院血液科江苏省血液研究所卫生部血栓与止血重点实验室,215006

出　　处：《白血病．淋巴瘤》2013年第6期335-338,共4页Journal of Leukemia & Lymphoma

基　　金：江苏高校优势学科建设工程资助项目;江苏省临床医学中心资助项目（ZX201102）;江苏省科技厅生命健康科技专项资金（BL2012005）;国家高技术研究发展计划（863计划）（201IAA020105）

摘　　要：滤泡性淋巴瘤（FL）是来源于滤泡生发中心的B细胞淋巴瘤。作为最常见的惰性淋巴瘤，FL总体预后较好，但其转归又具有异质性。利妥昔单抗的应用改善了疾病的疗效和预后。对于复发、难治患者，尤其是前期接受过含利妥昔单抗的一线方案治疗者，移植治疗是其重要选择。与传统清髓性预处理方案相比，减低强度预处理（RIC）方案降低了非复发死亡（NRM）率，扩展了可接受异基因移植的患者选择，但移植后复发率偏高是其主要缺陷。移植后应用供体淋巴细胞输注治疗可以减少和治疗疾病复发。未来，移植策略改进和新药应用会为FL治疗带来新的思路和机会。Follicular lymphoma （FL） is a subtype of B cell lymphoma, which derived from follicular germinal center. As the most common type of indolent lymphoma, the overall prognosis of FL is good. However, the prognosis of FL is heterogeneous. With the application of rituximab, the therapeutic effect and the prognosis of the disease is further improved. For the relapsed / refractory patients, especially who have received first-line chemotherapy with rituximab in the early, transplantation is an important choice. Compared with the previous conventional myeloablative conditioning regimen, reduced-intensity conditioning （RIC） effectively reduced the non-relapse mortality （NRM）, extended the allogeneic transplantation recipients, but the high rate of relapse after transplantation is the main defect. The application of donor lymphocyte infusion after transplantation therapy not only can reduce the recurrence rate but also treat the disease relapse. In the future, the improvement of transplantation strategy and the application of new drugs may bring new ideas and opportunities for FL therapy.

关 键 词：淋巴瘤 滤泡型 造血干细胞移植 利妥昔单抗 治疗 

分 类 号：R733[医药卫生—肿瘤]